Clinical Trials Sponsored by Veridex, LLC

Total 11039 results

Vericel Corporation

Recruiting

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK)

Chondral Defect | Articular Cartilage Disorder of Knee | Articular Cartilage Defect | Osteochondritis Dissecans (OCD)

United States
Vericel Corporation

Completed

Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee (SUMMIT)

Articular Cartilage Defect

Netherlands, Norway, France, Czechia, Sweden, Poland, United Kingdom
Vericel Corporation

Terminated

Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

Pseudarthrosis | Fracture, Ununited

United States
Vericel Corporation

Terminated

Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

Single Level Posterolateral Spinal Fusion
Vericel Corporation

Completed

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Dilated Cardiomyopathy

United States
Vericel Corporation

Completed

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) (ixCELLDCM)

Ischemic Dilated Cardiomyopathy (IDCM)

United States, Canada
Vericel Corporation

Completed

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee (Extension)

Articular Cartilage Defects

Norway, Netherlands, France, Czechia, Poland, Sweden, United Kingdom
Vericel Corporation

Completed

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia (RESTORE-CLI)

Peripheral Arterial Disease

United States
Vericel Corporation

Completed

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) (REVIVE)

Critical Limb Ischemia

United States
Vericel Corporation

Completed

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Dilated Cardiomyopathy

United States
Vericel Corporation

Completed

The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

Cartilage Diseases | Articular Cartilage

United States
Vericel Corporation

Completed

Study of the Treatment of Articular Repair (STAR)

Articular Cartilage

United States, Canada
Vericel Corporation

Completed

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head (ON-CORE)

Osteonecrosis

United States
Arthritis Northwest PLLC
Epigenesys LLC

Unknown

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

Arthritis, Rheumatoid

United States
Angle plc
MidLantic Urology, LLC

Terminated

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System (CHARTER)

Prostate Cancer | Castration-resistant Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | High Risk Prostate Carcinoma

United States
Hôpital Jean Verdier

Unknown

Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients (PRIMIV)

Breast Cancer | Fertility Preservation

France
Ostomycure AB
Veranex

Terminated

Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy

Ileostomy - Stoma

United Kingdom, Sweden
Novostia SA
Veranex

Recruiting

PILot Aortic Triflo Valve Study (PILATUS)

Aortic Valve Disease

Lithuania
NewAmsterdam Pharma
Veranex

Recruiting

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Synochi, LLC
LAC+USC Medical Center

Not yet recruiting

Prospective Placebo-controlled Study of Synochi Scar Spray

Burns Multiple
LLS PedAL Initiative, LLC
Kura Oncology

Not yet recruiting

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Relapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
Derm Research, PLLC
WFH MEDICAL, LLC

Completed

Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel

Acne Vulgaris

United States
Verily Life Sciences LLC
The Emmes Company, LLC; Optos, PLC; Google LLC.; Nikon Corporation

Completed

ARDA Software for the Detection of mtmDR

Diabetic Retinopathy

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

Pain
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathy

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
Vertex Pharmaceuticals Incorporated

Completed

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Pancreatic Cancer

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Vertex Pharmaceuticals Incorporated

Terminated

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Cystic Fibrosis

United States

3

Subscribe